Select Bibliography

Filter by any of these (after searching):

Blood

There are 149 items

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013

Abstract - Secondary - Primary - Leukemia - C10403

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010

Abstract - Primary - Preliminary - Leukemia - CALGB-10502

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study

Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461

Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720)

Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007

Abstract - Secondary - Primary - Leukemia - CALGB-8461 , CALGB-9720

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010

Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - Blood - 2010

Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance)

Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance)

Bill, Marius , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Approach in Patients (Pts) Treated on Cancer and Leukemia Group B/Alliance Protocols

Bill, Marius , Mrózek, Krzysztof , Kohlschmidt, Jessica ... - ASH - Blood - 2019

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-20202 , CALGB-8461 , CALGB-9665

A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance)

Bill, Marius , Nicolet, Deedra , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML)

Bill, Marius , Veneziano, Dario , Kohlschmidt, Jessica ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , C9665 , CALGB-20202

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008

Abstract - Primary - Primary - Lymphoma - CALGB-50502

Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study

Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010

Abstract - No-Endpoint - Comprehensive - Leukemia - CALGB-10503

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012

Abstract - Primary - Primary - Leukemia - CALGB-10503

Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies

Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Blood - 2013

Abstract - Secondary-not-in-original - Comprehensive - Leukemia - CALGB-9621 , CALGB-9710 , CALGB-10503 , CALGB-19808

Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL

Chen, S. S. , Claus, R. , Lucas, D. M. , Yu, L. , Qian, J. ... - - Blood - 2011

Manuscript - Secondary - Primary - Leuk Corr Sci - C9665 , C20305 , C9712

Acute Myeloid Leukemia (AML) with 9q aberrations occuring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)

Corbacioglu, A. , Frohling, S. , Paschka, P. , Marcucci, G. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-8461 , CALGB-9621 , CALGB-9665

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]

Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008

Abstract - Secondary - Primary - Lymphoma - CALGB-50402

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

DeAngelo, Daniel J. , Yu, Daohai , Johnson, Jeffrey L. ... - - Blood - 2007

Manuscript - Primary - Primary - Leukemia - CALGB-19801

Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production

Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012

Abstract - Primary - Preliminary - Leukemia - N1087

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013

Abstract - Primary - Primary - Leukemia - N1087

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - - Blood - 2020

Manuscript - No-Endpoint - Primary - Leuk Corr Sci - CALGB-10603

Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study

Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)

Edwards, C. G. , Maharry, K. , Mrozek, K. , Schwind, S. , Paschka, P. ... - - Blood - 2011

Abstract - Primary - Comprehensive - Leuk Corr Sci - CALGB-10503 , CALGB-19808 , CALGB-9621

Additional gene mutations refine the 2017 European Leukemianet (ELN) classification of adult patients (pts) with de novo acute myeloid leukemia (AML) aged <60 years: An analysis of Alliance studies

Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , CALGB-20202

Mutations in genes associated with familial predisposition to myeloid neoplasms:their frequency and associations with pretreatment characteristics in adult patients (pts) with presumably sporadic de novo acute myeloid leukemia (AML) (Alliance)

Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , CALGB-20202

MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-xxpressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML)

Eisfeld, Ann-Kathrin , Marcucci, G. , Maharry, K. , Schwind, S. ... - - Blood - 2011

Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Eisfeld, Ann-Kathrin , Marcucci, Guido , Maharry, Kati ... - - Blood - 2012

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-9665

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Transplant - CALGB-100101

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013

Abstract - Secondary - Primary - Lymphoma - CALGB-50403

Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Gallagher, R. E. , Moser, B. K. , Racevskis, J. , Poire, X. ... - - Blood - 2012

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - C9710

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710

Gallagher, R. E. , Moser, B. K. , Racevskis, J. , Poire, X. ... - - Blood - 2010

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C9710

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010

Abstract - Primary - Primary - Lymphoma - CALGB-50701

Dual Epigenetic Control of CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) Expression in Acute Myeloid Leukemia

Hackanson, B. , Bennett, K. L. , Brena, R. M. , Jiang, J. ... - - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML

Havelange, Violaine , Ranganathan, Parvathi , Geyer, Susan ... - - Blood - 2014

Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , C9720 , CALGB-10201 , CALGB-8923 , CALGB-9420

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Hickey, Christopher J. , Schwind, Sebastian , Radomska, Hanna S. ... - - Blood - 2013

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-9621 , CALGB-19808

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-50103

Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial (Alliance)

Jahn, Nikolaus , Panina, Ekaterina , Bullinger, Lars , Dolnik, Anna ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-10603

Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance)

Johnston, Patrick B. , LaPlant, Betsy R. , McPhail, Ellen D. ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - N1085

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials

Jones, J. A. , Stark, A. , Zhao, W. , Lin, T. S. , Rai, K. R. ... - - Blood - 2011

Abstract - Secondary-not-in-original - Comprehensive - Leukemia - CALGB-10101 , CALGB-19901

Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance)

Kaplan, Lawrence D. , Maurer, Matthew , Stock, Wendy , Fulton, Noreen ... - ASH - Blood - 2018

Abstract - Primary - Long-Term-Followup - Lymphoma - CALGB-50403

Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403

Kaplan, Lawrence D. , Stock, Wendy , Jung, Sin-Ho , Bartlett, Nancy ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - CALGB-50403

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia

Khandanpour, C. , Thiede, C. , Valk, P. J. , Sharif-Askari, E. ... - - Blood - 2010

Manuscript - Secondary - Primary - Leuk Corr Sci - C9665 , C8461

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808

Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007

Abstract - Primary - Preliminary - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Kolitz, Jonathan E. , George, Stephen L. , Marcucci, Guido ... - - Blood - 2010

Manuscript - Primary - Primary - Leukemia - CALGB-19808 , CALGB-8461

Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

Koval, G. , Wetzler, M. , Watson, D. , Owzar, K. , Bloomfield, C. D. ... - - Blood - 2011

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10001

A Comparison of Outcomes between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)

Kutny, Matthew A. , Geyer, Susan , Laumann, Kristina M ... - ASH - Blood - 2014

Abstract - Secondary-not-in-original - Primary - Leukemia - C9710

Effect of young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance)

Kutny, Matthew A. , Gregory, John , Geyer, Susan , Laumann, Kristina ... - ASH - Blood - 2014

Abstract - Secondary-not-in-original - Primary - Leukemia - C9710

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

Langer, Christian , Radmacher, Michael D. , Ruppert, Amy S. ... - - Blood - 2008

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017

Abstract - Secondary - Primary - Leukemia - CALGB-10603

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

Li, Z. , Huang, H. , Li, Y. , Jiang, X. , Chen, P. , Arnovitz, S. ... - - Blood - 2012

Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - C9665

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101

Lin, T. S. , Donohue, K. A. , Byrd, J. C. , Lucas, M. S. , Hoke, E. ... - - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-10101

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

Lin, T. S. , Donohue, K. A. , Lucas, M. S. , Byrd, J. C. ... - - Blood - 2007

Abstract - Primary - Preliminary - Leukemia - CALGB-10101

Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia

Link, Daniel C. , Kunter, Ghada , Kasai, Yumi , Zhao, Yu ... - - Blood - 2007

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9665

Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102)

Lozanski, G. , Sanford, B. , Mrozek, K. , Edwards, C. , Pearson, R. ... - ASH - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10102 , CALGB-8461 , CALGB-9665 , CALGB-9862

Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)

Malnassy, Greg , Geyer, Susan , Fulton, Noreen , Koval, Greg ... - - Blood - 2013

Abstract - Secondary-not-in-original - Meta-Analysis - Leuk Corr Sci - CALGB-10403 , CALGB-59909

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Mantha, Simon , Goldman, Debra A. , Devlin, Sean M. , Lee, Ju-Whei ... - - Blood - 2017

Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-9710

Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study

Marcucci, G. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20205 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance)

Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2014

Abstract - Primary - Primary - Leukemia - CALGB-10801

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2013

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10801

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Martin, Peter , Bartlett, Nancy L. , Blum, Kristie A. , Park, Steven ... - - Blood - 2019

Manuscript - Secondary-not-in-original - Primary - Lymphoma - NCT02159755

Oral Azacitidine (CC-486) Plus R-CHOP in Patients With High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Martin, Peter , Bartlett, Nancy L. , Chavez, Julio C. ... - ASH - Blood - 2018

Abstract - Primary - Primary - Lymphoma - AFT-08

A phase I, open–label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)

Martin, Peter , Bartlett, Nancy L. ... - ASH - Blood - 2017

Abstract - Primary - Primary - Lymphoma - AFT-08

Diagnosis to treatment interval (DTI) is associated with adverse outcome in newly diagnosed patients with mantle cell lymphoma, a MER/LEO and Alliance collaboration

Maurer, Matthew J. , Ruppert, Amy S. , Link, Brian K. ... - ASH - Blood - 2018

Abstract - Primary - Primary - Lymphoma - A151814

Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)

McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Mccarthy, P. L. , Owzar, K. , Anderson, K. C. , Hofmeister, C. C. ... - - Blood - 2010

Abstract - Primary - Primary - Transplant - CALGB-100104

Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures

Mendler, J. H. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2011

Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9720

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category

Metzeler, K. H. , Becker, H. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2011

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups

Metzeler, K. H. , Hummel, M. , Bloomfield, C. D. , Spiekermann, K. ... - - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9621 , CALGB-9665

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

Metzeler, K. H. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2010

Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , C8641 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Metzeler, Klaus H. , Becker, Heiko , Maharry, Kati ... - - Blood - 2011

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

Metzeler, Klaus H. , Hummel, Manuela , Bloomfield, Clara D. ... - - Blood - 2008

Manuscript - Secondary-not-in-original - Meta-Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9621 , CALGB-9665

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Micallef, Ivana N. M. , Maurer, Matthew J. , Wiseman, Gregory A. ... - - Blood - 2011

Manuscript - Primary - Primary - Lymphoma - N0489

Development and Validation of a Dominant Clone Precision Medicine Classification for Treatment of Elderly Acute Myeloid Leukemia (Alliance)

Mims, Alice S. , Borate, Uma , Kohlschmidt, Jessica , Norris, Brianna ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , CALGB-20202

Comparisons between TP53 mutations and TP73 mutations in adult acute myeloid leukemia (AML) (Alliance)

Mims, Alice S. , Kohlschmidt, Jessica , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , CALGB-20202

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Moore, Joseph O. , George, Stephen L. , Dodge, Richard K. ... - - Blood - 2005

Manuscript - Primary - Primary - Leukemia - CALGB-9222

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)

Morrison, V. A. , Peterson, B. L. , Rai, K. R. , Byrd, J. C. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original - Meta-Analysis - Leukemia - C9011 , CALGB-19901 , CALGB-9712

Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes in Adults: a Cancer and Leukemia Group B (CALGB) Study

Mrozek, K. , Holland, K. B. , Pettenati, M. J. , Maharry, K. ... - ASH - Blood - 2009

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - Comprehensive

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

Mrozek, K. , Marcucci, G. , Maharry, K. , Nicolet, D. , Becker, H. ... - - Blood - 2011

Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Molecular landscape and clinical features of acute myeloid leukemia (AML) with complex karyotype (CK) CALGB 20202 and 8461 (Alliance)

Mrózek, Krzysztof , Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Mrózek, Krzysztof , Marcucci, Guido , Paschka, Peter ... - - Blood - 2007

Manuscript - No-Endpoint - Other - Leuk Corr Sci - No Study Assigned

Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)

Muffly, L. S. , Stock, W. , Breitenbach, K. , Mulkey, F. , Luger, S. ... - ASH - Blood - 2012

Abstract - Secondary-not-in-original - Primary - Disparities - CALGB-10403 , C10403

Concomitant use of midostaurin with Strong CYP3A4 inhibitors: An analysis from the CALGB 10603/RATIFY Trial (Alliance)

Ouatas, Taoufik , Duval, Vincent , Sinclair, Karen ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Papaioannou, Dimitrios , Maharry, Kati , Mrózek, Krzysztof ... - ASH - Blood - 2013

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-9665 , CALGB-8461

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic MicroRNAs (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Papaioannou, Dimitrios , Nicolet, Deedra , Archer, Kellie J. ... - ASH - Blood - 2019

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Recurrent Genetic Variants of Long Non-Coding RNAs Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia (ALLIANCE/CALGB 8461, 9665, 20202)

Papaioannou, Dimitrios , Ozer, Gulcin H. , Nicolet, Deedra ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study

Paschka, P. , Marcucci, G. , Ruppert, A. S. , Mrozek, K. ... - - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Powell, B. L. , Moser, B. K. , Stock, W. , Gallagher, R. E. ... - - Blood - 2011

Abstract - Secondary - Primary - Leukemia - C9710

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

Powell, Bayard L. , Moser, Barry , Stock, Wendy ... - - Blood - 2010

Manuscript - Primary - Primary - Leukemia - C9710

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Rai, K. R. , Peterson, B. L. , Appelbaum, F. R. , Tallman, M. S. ... - ASH - Blood - 2009

Abstract - Primary - Long-Term-Followup - Leukemia - C9011

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - - Blood - 2010

Abstract - Primary - Primary - Leukemia - CALGB-10002

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Rosenbaum, Cara A. , Pitcher, Brandelyn , Bartlett, Nancy L ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - CALGB-50901

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

Rubenstein, J. L. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2010

Abstract - Primary - Primary - Lymphoma - CALGB-50202

Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)

Rücker, Frank G. , Du, Ling , Blätte, Tamara J. , Benner, Axel ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Aberrant Gene Expression of BAALC and ERG in Older >= 60 Years (y) De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study

Schwind, S. , Marcucci, G. , Maharry, K. , Mrozek, K. ... - - Blood - 2009

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720

inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Schwind, Sebastian , Edwards, Colin G. , Nicolet, Deedra ... - - Blood - 2013

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-8525 , CALGB-8821 , CALGB-8923 , CALGB-9022 , CALGB-9120 , CALGB-9222 , CALGB-9621 , CALGB-9720 , CALGB-19808 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

Schwind, Sebastian , Marcucci, Guido , Kohlschmidt, Jessica ... - - Blood - 2011

Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Schwind, Sebastian , Marcucci, Guido , Maharry, Kati ... - - Blood - 2010

Manuscript - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-8923 , CALGB-9420 , CALGB-9720

Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.

Schöder, Heiko , Polley, Mei-Yin , Knopp, Michael V , Hall, Nathan C ... - - Blood - 2020

Manuscript - Secondary - Primary - Lymphoma - CALGB-50303

Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901

Shea, T. C. , Johnston, J. , Walsh, W. , Farag, S. , Mccarty, J. ... - - Blood - 2007

Abstract - Primary - Primary - Transplant - CALGB-109901

Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014

Abstract - Secondary - Meta-Analysis - Lymphoma - A051201 , A051202

Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401)

Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015

Abstract - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)

Stock, W. , Sanford, B. , Lozanski, G. , Vij, R. , Byrd, J. C. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-10102

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Stock, Wendy , La, Mei , Sanford, Ben , Bloomfield, Clara D. ... - - Blood - 2008

Manuscript - Secondary-not-in-original - Meta-Analysis - Leukemia - CALGB-8811 , CALGB-9331 , CALGB-19802 , CALGB-8461 , CALGB-9111 , CALGB-9511

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Stock, Wendy , Luger, Selina M. , Advani, Anjali S. , Yin, Jun ... - - Blood - 2019

Manuscript - Primary - Primary - Leukemia - CALGB-10403

Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014

Abstract - Primary - Preliminary - Leukemia - CALGB-10403

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance])

Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2015

Abstract - Secondary - Primary - Leukemia - CALGB-10603

Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203

Straus, D. J. , Lacasce, A. S. , Juweid, M. E. , Kostakoglu, L. ... - - Blood - 2007

Abstract - Primary - Primary - Lymphoma - CALGB-50203

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Straus, David J. , Johnson, Jeffrey L. , LaCasce, Ann S. ... - - Blood - 2011

Manuscript - Primary - Primary - Lymphoma - CALGB-50203

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018

Manuscript - Primary - Primary - Lymphoma - CALGB-50604

Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015

Abstract - Primary - Preliminary - Lymphoma - CALGB-50604

Toxicities and related outcomes of elderly patients (≥65 years) with hematologic malignancies in the contemporary era (Alliance A151611)

Tallarico, Michael , Foster, Jared , Seisler, Drew ... - ASH - Blood - 2016

Abstract - Primary - Primary - Older Adult - A151611 , CALGB-10101 , CALGB-10404 , CALGB-10501 , CALGB-19805 , CALGB-19901 , CALGB-50002 , CALGB-50103 , CALGB-50201 , CALGB-50401 , CALGB-50402 , CALGB-50501 , CALGB-50602 , CALGB-50701 , CALGB-50803

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Tallman, M. S. , Kim, H. T. , Montesinos, P. , Appelbaum, F. R. ... - - Blood - 2010

Manuscript - Secondary-not-in-original - Primary - Leukemia - INT-0129

The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML - Results of an international metaanalysis

Thiede, C. , Bloomfield, C. D. , Lo Coco, F. , Frohling, S. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original - Comprehensive - Leuk Corr Sci - CALGB-19808 , CALGB-8461 , CALGB-9621 , CALGB-9665

FLT3 mutation assay laboratory cross validation: results from the CALGB 10603/RATIFY(Alliance) trial in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Thiede, Christian , Prior, Thomas , Coco, Francesco Lo ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

Tomasson, Michael H. , Xiang, Zhifu , Walgren, Richard , Zhao, Yu ... - - Blood - 2008

Manuscript - Secondary-not-in-original - Meta-Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-9621 , CALGB-9665

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Ujjani, Chaitra S. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2016

Manuscript - Primary - Primary - Lymphoma - A051103

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Ujjani, Chaitra , Jung, Sin-Ho , Pitcher, Brandelyn , Martin, Peter ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - A051103

Allogeneic Hematopoietic Cell Transplantation (HCT) vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG and CIBMTR Study

Ustun, Celalettin , Le-Rademacher, Jennifer G , Wang, Hailin ... - ASH - Blood - 2018

Abstract - Primary - Primary - Leukemia - A151509 , CALGB-100103

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001).

Uy, Geoffrey L. , Mandrekar, Sumithra , Laumann, Kristina ... - ASH - Blood - 2015

Abstract - Primary - Primary - Leukemia - CALGB-11001

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013

Abstract - Primary - Preliminary - Leukemia - CALGB-11001

CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy

Vij, Ravi , Hars, Vera , Shea, Thomas , Hoke, Eva , Blum, William ... - ASH - Blood - 2014

Abstract - Secondary - Primary - Transplant - CALGB-100801

Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFEN study update (AFT-29)

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - ASH - Blood - 2019

Abstract - Secondary - Primary - Myeloma - AFT-29

Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)

Voorhees, Peter M. , Morris, Michael , Costa, Luciano J. , PhD ... - ASH - Blood - 2017

Abstract - Secondary - Preliminary - Myeloma - AFT-29

Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Voorhees, Peter M. , Mulkey, Flora , Hassoun, Hani ... - ASH - Blood - 2015

Abstract - Primary - Primary - Myeloma - A061202

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - ASH - Blood - 2018

Abstract - Primary - Primary - Myeloma - AFT-29

RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance)

Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603

Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Walker, Christopher J. , Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , CALGB-20202

Distinct Gene Expression Profiles and Mutations Are Associated with Disease Relapse after Achievement of Complete Remission (CR) in Adult Patients younger than 60 years with de novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Walker, Christopher J. , Eisfeld, Ann-Kathrin , Ozer, Hatice Gulcin ... - ASH - Blood - 2019

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665

Genome-wide association study (GWAS) identifies a significant acute myeloid leukemia (AML) susceptibility locus near BICRA (Alliance)

Walker, Christopher J. , Oakes, Christopher C. , Genutis, Luke K. ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - C8461 , CALGB-20202

High resolution array-based CGH and SNP studies of AML genomes

Walter, M. J. , Ries, R. , Li, X. , Shannon, W. , Payton, J. ... - ASH - Blood - 2007

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9665

Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001

Wetzler, M. , Stock, W. , Donohue, K. A. , Owzar, K. , Sher, D. A. ... - - Blood - 2007

Abstract - Primary - Primary - Leukemia - CALGB-10001 , CALGB-8461 , CALGB-9665 , CALGB-9862

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Wetzler, M. , Watson, D. , Stock, W. , Owzar, K. , Koval, G. , Hoke, E. ... - - Blood - 2012

Abstract - Primary - Primary - Leukemia - CALGB-10001

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Wetzler, Meir , Sanford, Ben L. , Kurtzberg, Joanne ... - - Blood - 2007

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9511

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older >= 60 Years (Y) De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study

Whitman, S. P. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2009

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

Whitman, S. , Kohlschmidt, J. , Maharry, K. , Nicolet, D. ... - - Blood - 2012

Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9665 , CALGB-20202

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

Whitman, Susan P. , Hackanson, Björn , Liyanarachchi, Sandya ... - - Blood - 2008

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-20502 , CALGB-9665 , CALGB-9769

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Whitman, Susan P. , Maharry, Kati , Radmacher, Michael D. ... - - Blood - 2010

Manuscript - Secondary - Primary - Leuk Corr Sci - C8461 , C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study

Whitman, Susan P. , Ruppert, Amy S. , Marcucci, Guido ... - - Blood - 2007

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665 , CALGB-9769

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

Whitman, Susan P. , Ruppert, Amy S. , Radmacher, Michael D. ... - - Blood - 2008

Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)

Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoff ... - ASH - Blood - 2016

Abstract - Secondary - Primary - Leukemia - CALGB-10701

A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed PH/BCR-ABL1-positive acute lymphoblastic leukemia: Final results of Alliance/CALGB study 10701

Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoff ... - ASH - Blood - 2018

Abstract - Primary - Primary - Leukemia - CALGB-10701

Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303

Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016

Abstract - Primary - Primary - Lymphoma - CALGB-50303

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Woyach, J. A. , Ruppert, A. S. , Peterson, B. , Rai, K. R. ... - - Blood - 2011

Abstract - Secondary-not-in-original - Meta-Analysis - Leukemia - C9011 , CALGB-10101 , CALGB-9712

Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712

Woyach, J. , Heerema, N. A. , Stark, A. , Peterson, B. L. ... - - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-9712

Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202

Woyach, Jennifer A. , Ruppert, Amy S. , Heerema, Nyla ... - ASH - Blood - 2018

Abstract - Primary - Primary - Leukemia - A041202

Event-free survival as a surrogate endpoint for overall survival in previously untreated acute myeloid leukemia: An individual patient-level analysis of multiple randomized trials (Alliance A151614)

Yin, Jun , LaPlant, Betsy , Storrick, Elizabeth , Uy, Geoffrey L. ... - ASH - Blood - 2018

Abstract - Primary - Comprehensive - Leukemia - A151614 , CALGB-10201 , E1900 , CALGB-10603 , S0106